Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2023 Earnings Presentation
12 slides from Alkem Laboratories's earnings presentation, Aug 5, 2022
Slide 1: Investor Presentation Q1FY23
Investor Presentation Q1FY23 August 5, 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q1FY23
Key Highlights of Q1FY23 • Revenue from Operations declined by 5.7% YoY during the quarter, with EBITDA margin of 7.9% and Net Profit decline of 72.7% YoY • India Business: Company’s secondary sales remained flat compared to IPM decline of 1.8% YoY (Source: IQVIA data) • Market beating performance i
Slide 4: Key Financial Highlights – Q1FY23 (Consolidated)
Key Financial Highlights – Q1FY23 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 19,097 17,815 27,314 25,764 Q1FY22 Q1FY23 International sales 7,903 7,604 Q1FY22 Q1FY23 Q1FY22 Q1FY23
Slide 5: Key Financial Highlights – Q1FY23 (Consolidated)
Key Financial Highlights – Q1FY23 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 16,366 14,810 5,929 2,032 59.9% 57.5% 21.7% 7.9% Q1FY22 Q1FY23 Q1FY22 Q1FY23 PBT (before Minority Interest) PAT (after Minority Interest) 4,681 5,561 1,519 1,276 Q1FY22 Q1FY23
Slide 6: India Business
India Business India Business: Q1FY23 Sales of ₹ 17,815 million (6.7% YoY decline) • India sales contributed 70.1% to total sales in Q1FY23 • In Q1FY23, the Company’s secondary sales remained flat compared to IPM decline of 1.8% YoY (Source: IQVIA data) • Outperformance was mainly led by acute thera
Slide 7: Secondary Sales Performance
Secondary Sales Performance Market beating performance across major therapeutic segments in Q1FY23 +1 Market rank 1 3 3 2 Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 19.3% 12.9% 10.0% 10.1% -7.8% -12.4% -12.7% -17.9% Alkem sales growth YoY1,2 Ind
Slide 8: US Business
US Business US Business: Q1FY23 Sales of ₹ 5,565 million (YoY decline of 7.9%) • US sales contributed 21.9% to total sales in Q1FY23 • During the quarter, the US business registered sequential growth of 2.7% over Q4FY22 • In Q1FY23, the Company filed 3 ANDAs with the US FDA and received 4 approvals
Slide 9: US Business: Update on US FDA inspections
US Business Update on US FDA inspections Facility Capability Last inspection Status post last inspection Received 1 observation. The Company has already submitted a detailed Indore Formulations July 2022 response to the US FDA on the corrective and preventive actions it is taking to address them. Re
Slide 10: Other International Business
Other International Business Other International Business: Q1FY23 Sales of ₹ 2,039 million (9.6% YoY growth) • Other International Market sales contributed 8.0% to total sales in Q1FY23 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key markets like
Slide 11: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on June 30, 2022 Non-Institution, 23.09% Promoter & Promoter Group, 57.14% Institution, 19.77% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodie
Slide 12: Thank You
Thank You For further information or queries, please contact Amit Kumar Khandelia AVP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com